211 related articles for article (PubMed ID: 12936969)
41. Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model.
Hershberger E; Rybak MJ
Antimicrob Agents Chemother; 2000 Mar; 44(3):598-601. PubMed ID: 10681324
[TBL] [Abstract][Full Text] [Related]
42. Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept.
Firsov AA; Shevchenko AA; Vostrov SN; Zinner SH
Antimicrob Agents Chemother; 1998 Mar; 42(3):659-65. PubMed ID: 9517948
[TBL] [Abstract][Full Text] [Related]
43. The effect of pharmacokinetic/pharmacodynamic (PK/PD) parameters of gatifloxacin on its bactericidal activity and resistance selectivity against clinical isolates of Streptococcus pneumoniae.
Ebisu H; Kishii R; Takei M; Fukuda H
J Infect Chemother; 2003 Sep; 9(3):210-4. PubMed ID: 14513387
[TBL] [Abstract][Full Text] [Related]
44. Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against Staphylococcus aureus and Streptococcus pneumoniae.
Lepak AJ; Zhao M; Liu Q; Wang P; Wang Y; Bader JC; Ambrose PG; Andes DR
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30559140
[TBL] [Abstract][Full Text] [Related]
45. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
Klepser ME; Ernst EJ; Petzold CR; Rhomberg P; Doern GV
Antimicrob Agents Chemother; 2001 Mar; 45(3):673-8. PubMed ID: 11181341
[TBL] [Abstract][Full Text] [Related]
46. An in vivo study comparing the ocular absorption of levofloxacin and ciprofloxacin prior to phacoemulsification.
Bucci FA
Am J Ophthalmol; 2004 Feb; 137(2):308-12. PubMed ID: 14962422
[TBL] [Abstract][Full Text] [Related]
47. Efficacy of levofloxacin in the treatment of experimental endocarditis caused by viridans group streptococci.
Entenza JM; Caldelari I; Glauser MP; Moreillon P
J Antimicrob Chemother; 1999 Dec; 44(6):775-86. PubMed ID: 10590278
[TBL] [Abstract][Full Text] [Related]
48. In vivo efficacy of a new quinolone, DQ-113, against Streptococcus pneumoniae in a mouse model.
Otsu Y; Yanagihara K; Fukuda Y; Miyazaki Y; Tsukamoto K; Hirakata Y; Tomono K; Kadota J; Tashiro T; Murata I; Kohno S
Antimicrob Agents Chemother; 2003 Dec; 47(12):3699-703. PubMed ID: 14638468
[TBL] [Abstract][Full Text] [Related]
49. Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model.
Andes D; Stamsted T; Conklin R
Antimicrob Agents Chemother; 2001 Mar; 45(3):922-6. PubMed ID: 11181381
[TBL] [Abstract][Full Text] [Related]
50. Pharmacodynamically Guided Levofloxacin Dosing for Pediatric Community-Acquired Pneumonia.
Courter JD; Nichols KR; Kazazian C; Girotto JE
J Pediatric Infect Dis Soc; 2017 Jun; 6(2):118-122. PubMed ID: 26903555
[TBL] [Abstract][Full Text] [Related]
51. In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
Andes D; Craig WA
Antimicrob Agents Chemother; 2007 May; 51(5):1633-42. PubMed ID: 17307987
[TBL] [Abstract][Full Text] [Related]
52. Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae.
Noreddin AM; Hoban DJ; Zhanel GG
Int J Antimicrob Agents; 2005 Aug; 26(2):120-5. PubMed ID: 16046101
[TBL] [Abstract][Full Text] [Related]
53. In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone.
Otani T; Tanaka M; Ito E; Kurosaka Y; Murakami Y; Onodera K; Akasaka T; Sato K
Antimicrob Agents Chemother; 2003 Dec; 47(12):3750-9. PubMed ID: 14638477
[TBL] [Abstract][Full Text] [Related]
54. Simulated comparison of the pharmacodynamics of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration data.
Burgess DS; Hall RG
Clin Ther; 2007 Jul; 29(7):1421-7. PubMed ID: 17825693
[TBL] [Abstract][Full Text] [Related]
55. Pharmacodynamics of 750 mg and 500 mg doses of levofloxacin against ciprofloxacin-resistant strains of Streptococcus pneumoniae.
Lister PD
Diagn Microbiol Infect Dis; 2002 Sep; 44(1):43-9. PubMed ID: 12376030
[TBL] [Abstract][Full Text] [Related]
56. In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model.
Andes D; van Ogtrop M
Antimicrob Agents Chemother; 2000 Apr; 44(4):938-42. PubMed ID: 10722494
[TBL] [Abstract][Full Text] [Related]
57. The pharmacodynamics of gatifloxacin and ciprofloxacin for pneumococci in an in vitro dynamic model: prediction of equiefficient doses.
Zinner SH; Firsov AA; Gilbert D; Simmons K; Lubenko IY
J Antimicrob Chemother; 2001 Dec; 48(6):821-6. PubMed ID: 11733466
[TBL] [Abstract][Full Text] [Related]
58. Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models.
Bulik CC; Okusanya ÓO; Lakota EA; Forrest A; Bhavnani SM; Hoover JL; Andes DR; Ambrose PG
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872075
[TBL] [Abstract][Full Text] [Related]
59. In vivo oral efficacy of levofloxacin for treatment of systemic Pseudomonas aeruginosa infections in a murine model of septicemia.
Yagel SK; Barrett JF; Amaratunga DJ; Frosco MB
Antimicrob Agents Chemother; 1996 Dec; 40(12):2894-7. PubMed ID: 9124863
[TBL] [Abstract][Full Text] [Related]
60. Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects.
Conte JE; Golden JA; McIver M; Zurlinden E
Int J Antimicrob Agents; 2006 Aug; 28(2):114-21. PubMed ID: 16837169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]